Pfizer said it wants to boost market share in Asiafrom its current 4% to 6% by 2012 and will expand operations in China from the 110 cities currently served to more than 650 cities.
The company also confirmed the numbers of experimental drugs in its pipeline from mid to late satge testing will range from 15 to 20 by the end of 2009. To stave off generic competition, at the same time, it will grow its Phase 3 programs by 50 to 75% to between 24 and 28 programs from the current 16.
It also confirms it is speeding up clinical development on 20 programmes but will terminate 24 clinical and pre-clinical programmes to reinvest in high value areas.
Pfizer says it has 26 biotec drugs spanning 8 treatment areas and aims to become a top tier biotherapeutics company. It will also form a new business unit to focus solely on cancer drugs